News >

FDA Grants Priority Review to Tucatinib in HER2+ Breast Cancer

Jason M. Broderick
Published: Thursday, Feb 13, 2020

The FDA has granted a priority review designation to a new drug application (NDA) for tucatinib for use in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, following at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant, or metastatic setting.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication